Symbols

GUTS

Fractyl Health·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

RSI Overbought

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GUTS

Fractyl Health, Inc.

A diabetes and obesity therapy research and development company

Industry

Life Science Tools and Services

Established Date

08/30/2010

Listing Date

02/02/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

107

Fiscal Year Ends

12-31

Website

www.fractyl.com

Security Type

Common stock

Office address

3 Van de Graaff Drive, Suite 200, Burlington, MA 01803

Business

Introduction

Fractyl Health, Inc., was incorporated under the laws of the State of Delaware on August 30, 2010. The company is a metabolic therapy company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. About 100 million people in the United States have prediabetes and obesity, and another 25 million have diabetes and are on medication, according to the Centers for Disease Control and the International Diabetes Federation. The company's goal is to develop durable disease-modifying therapies designed to provide long-term maintenance of metabolic health without the need for lifelong treatment by targeting the organ-level root causes of T2D and obesity.

Earnings Call

Q1/2025

Estimate EPS-0.5

Actual EPS-0.46

Estimate Revenue--

Actual Revenue0

Fractyl Health's Q1 2025 Earnings Call: Key Contradictions in Clinical Trial Progress and Regulatory Pathways

May 20,2025 03:51·
Earnings Decrypt

Q2/2025

Estimate EPS-0.36

Actual EPS-0.55

Estimate Revenue--

Actual Revenue0

Fractyl Health's 2025 Q2 Earnings Call: Unpacking Key Contradictions in IND Clearance, Weight Management, and Market Strategy

Aug 12,2025 08:28·
Earnings Decrypt

Company Financials

EPS

GUTS has released its 2025 Q3 earnings. EPS was reported at -0.71, versus the expected -0.32, missing expectations. The chart below visualizes how GUTS has performed over recent quarters, highlighting trends in earnings surprises.